DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

It takes the form of a patch with a small needle that pierces the skin and is worn on the back of the arm for up to 15 days, communicating glucose readings to a smartphone. Dexcom is focused on ...

Instead, I’ve been checking my glucose levels. That’s because on the underside of my left arm is a Dexcom Stelo continuous glucose monitor (CGM). Some days, I’m relieved by what I see.

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to know about glucose monitoring. Jessica is a writer on the Wellness ...

SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third ...

Dexcom‘s Stelo glucose monitor is for those ... There was a tiny pin prick when I activated the device, which poked a needle into my skin. After that, I couldn’t feel it anymore.

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...